$BCAB Income Statement | Understand Stock

$BCAB

$1.74 +$0.00 (0.0%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Collaboration and other revenue
Operating expenses:
Research and development expense
General and administrative expense
Total operating expenses
Loss from operations
Other income (expense):
Interest income
interest expense
Gain on extinguishment of long-term debt
Gain on warrant liability
Loss on PPAs liability
Other expense
Total other income (expense)
Consolidated net loss and comprehensive loss
Net loss attributable to noncontrolling interests
Net loss attributable to BioAtla, Inc./BioAtla LLC

Net loss per common share, basic and diluted
Weighted-average shares of common stock outstanding, basic and diluted
Net loss per common share, basic
Net loss per common share, diluted
Weighted-average shares of common stock outstanding, basic
Weighted-average shares of common stock outstanding, diluted

Comments